White House officials assured the drug industry that drug reimportation will not be necessary once a health care bill that promises larger cost savings is passed, said Billy Tauzin, president of the Pharmaceutical Research and Manufacturers of America. Tauzin was among the industry representatives meeting at the White House to discuss a cost-savings agreement reached last month with health care negotiators.

Related Summaries